Journal
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Volume 930, Issue -, Pages 129-135Publisher
ELSEVIER
DOI: 10.1016/j.jchromb.2013.05.003
Keywords
Alzheimer's disease (AD); Biomarker; Cerebrospinal fluid (CSF); Targeted proteomics; Multiple reaction monitoring (MRM)
Funding
- National Institutes of Health [R01MH59926, 2P20RR016472, 5P30RR031160]
- New York State Office of Science, Technology, and Academic Research
- Institute for the Study of Aging
Ask authors/readers for more resources
There is significant interest in the development of methods to validate novel biomarkers for Alzheimer's disease (AD) diagnosis. Previously, a proteomic panel of cerebrospinal fluid (CSF) biomarker candidates that differentiated AD and non-AD CSF with accuracy higher than 90% was found; information about these CSF proteins can be used to develop multiple reaction monitoring (MRM) based analytical assays, which offer the possibility of quantifying protein expression level changes in samples, as well as, validation among multiple laboratories. Here we report an MRM assay that demonstrates good linearity (average R-2 = 0.969) and reproducibility (average coefficient of variance of 6.93%) for the proposed AD CSF biomarkers. MRM quantification results of A beta 1-40, A beta 1-42, retinol-binding protein and cystatin C correlated well with those from ELISA (average R-2 = 0.974). Analysis shows that 12 out of 16 selected targets exhibit the same trend in protein expression as that in literature. (C) 2013 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available